MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Myeloid cell leukemia sequence 1 (MCL-1) and B cell leukemia/lymphoma 2 (BCL-2) are anti-apoptotic proteins in the BCL-2 protein family often expressed in cancer. To compare the function of MCL-1 and BCL-2 in maintaining cancer survival, we constructed complementary mouse leukemia models based on Eμ-Myc expression in which either BCL-2 or MCL-1 are required for leukemia maintenance. We show that the principal anti-apoptotic mechanism of both BCL-2 and MCL-1 in these leukemias is to sequester pro-death BH3-only proteins rather than BAX and BAK. We find that the MCL-1–dependent leukemias are more sensitive to a wide range of chemotherapeutic agents acting by disparate mechanisms. In common across these varied treatments is that MCL-1 protein levels rapidly decrease in a proteosome-dependent fashion, whereas those of BCL-2 are stable. We demonstrate for the first time that two anti-apoptotic proteins can enable tumorigenesis equally well, but nonetheless differ in their influence on chemosensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315 · cited 1×
“PUMA is a pro-apoptotic BH3-only protein first identified as a transcriptional target of p53 (Nakano and Vousden, 2001).”
BackgroundHypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300 · cited 1×
“Conditions which often occur in cancer, such as growth factor and/or oxygen deprivation, can sensitize MYC-expressing cells to apoptosis (Evan et al., 1992; Graeber et al., 1996; Brunelle et al., 2004).”
BackgroundLetai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Self-citationKuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185 · cited 1×
“This observation is more consistent with a model in which the most important antiapoptotic function of anti-apoptotic proteins like BCL-2 or MCL-1 is to sequester BH3-only proteins (Cheng et al., 1996; Cheng et al., 2001; Letai et al., 2002; Kuwana et al., 2005; Certo et al., 2006).”
ResultMaurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819 · cited 2×
“Note that p53 upregulation, indicating a defect in the ARF/Mdm2/p53 tumor suppressor pathway, was found in 10 of 11 E-Myc samples tested, a higher proportion than was reported previously (Eischen et al., 1999).”
ResultDissecting eIF4E action in tumorigenesis
Wendel, H.-G., Silva, R. L. A., Malina, A., Mills, J. R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., et al. (2007) · Genes & Development · doi:10.1101/gad.1604407 · Cited by 487 · cited 1×
“In murine bone marrow viral infection models, MCL-1 was found to accelerate both myeloid and lymphoid malignancies (Wendel et al., 2007; Beverly and Varmus, 2009).”
Background
Cited by
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
Self-citationPretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P., Tai, Y.-T., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 585
Self-citationFernald, K., & Kurokawa, M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.006 · Cited by 579
The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy
Kelly, P. N., & Strasser, A. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.17 · Cited by 453
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Yecies, D., Carlson, N. E., Deng, J., & Letai, A. (2010) · Blood · doi:10.1182/blood-2009-07-233304 · Cited by 360
Self-citation
Metadata
- Authors
- Brunelle, J. K., Ryan, J., Yecies, D., Opferman, J. T., & Letai, A.
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2009-10-26
- Volume
- 187
- Issue
- 3
- Pages
- 429-442
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- OpenAlex
- W2125499510
- Cited by
- 87
- References
- 8
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.